Company Overview
Thermo Fisher Scientific Inc operates in the Life Sciences Tools & Services industry and is based in the United States. The company provides analytical instruments, laboratory equipment, and related services to research and healthcare customers. It has approximately 371 million shares outstanding and a market capitalization of about USD 172.5 billion. Its operations span multiple scientific and healthcare markets, serving both research and applied sectors.
Analysis of recent data
FundamentalsThermo Fisher reported USD figures for 2025 with revenue of 44.56 billion, EBIT of 7.75 billion, and net income of 6.72 billion. Revenue grew 3.91% year over year, showing modest top-line expansion. The company maintained a 41.09% gross margin and a 17.38% operating margin, reflecting consistent profitability.
Return on equity stood at 13.11%, while the net profit margin reached 15.03%. Cash holdings were 9.85 billion, and total debt was not provided, limiting balance sheet assessment. The firm’s return-
Overall, the latest data indicate stable margins and solid returns on equity, supported by steady revenue growth and a strong cash position.
Valuation
DCF / MultiplesAt USD 464.37 per share, the stock trades above the DCF base case. The DCF fair-value range is 311.69 (bear), 433.97 (base), and 566.43 (bull). This suggests the market is pricing in continued profitability and stable margins.
With a trailing PE of 25.75 and an EV/EBITDA of 22.12, investors appear willing to pay a premium for consistent returns. The valuation implies confidence that the company can sustain its 17.38% operating margin and 13.11% ROE over time.
Conclusion
TakeawayThermo Fisher continues to deliver reliable profitability and steady growth. The market seems to expect these returns to persist. While the valuation is slightly above the base case, it reflects confidence in the business model. Investors may prefer to wait for a wider margin of safety before adding exposure.